PRESS RELEASE

Piramal Pharma Solutions' Pithampur, India Site Wins Annual Excellence in Patient Centricity Award for Linking Every Batch to Patient Impact

- *Pithampur's Patient Awareness Council (PAC) won for creating the Integrated Patient Impact Dashboard, which provides visibility into the site's operational output and the patient lives affected by that work.*
- *The annual Excellence in Patient Centricity Award recognizes the PAC that led the year's most impactful Patient Centricity initiative.*
- *Piramal has established PACs at its 15 global sites. These groups organize initiatives to educate employees and embed a patient-centric ethos across the company.*

Mumbai, India | October 28, 2026: Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA | BSE: 543635), today announced that the Patient Awareness Council (PAC) at its drug product manufacturing site in Pithampur, India has won this year's Excellence in Patient Centricity Award.

The Pithampur PAC was honored for "Beyond the Batch: Connecting Our Work to Every Patient," the project that led to the Integrated Patient Impact Dashboard. This dashboard consolidates supply, production, and customer insights into one streamlined digital platform, giving internal and external stakeholders visibility into how operational output affects patient lives. It turns once-fragmented data into a clear story of patient reach, customer value, business performance, and employee contribution.

The dashboard tracks production volumes, monthly supply trends, product-wise contribution, potential patient reach, and Patient Centricity initiatives all in one place, creating a direct line of sight from the site's operational scale to its downstream patient impact. Today, it shows that Pithampur delivers an average monthly supply of 39.8 million units across 24 products, potentially touching 34.08 million lives.





"We are incredibly proud of the Pithampur PAC for creating the Integrated Patient Impact Dashboard, reminding us that we aren't just delivering a batch or a product; we are delivering hope for patients," said Stu Needleman, Chief Commercial Officer and Chief Patient Centricity Officer, Piramal Pharma Solutions. "This effort gives purpose to every batch and transforms Patient Centricity from a philosophical concept into a visible metric that the entire organization contributes to. It also shows how connecting our function with our purpose can lead to better quality, greater customer confidence, and stronger business outcomes."

Every batch represents a chain of responsibility, running from manufacturing all the way to patient impact, and the dashboard helps employees see where their work fits in that journey. This visibility has shifted mindsets across Pithampur's teams from "this is my task" to "this is my contribution to the patient," strengthening ownership, accountability, quality, patient safety, and sense of purpose. The dashboard has also improved decision-making by making trends easier to understand and helping teams take data-informed action.



That shift is also visible to customers, who have praised the site's diligence, responsiveness, and adaptability – strengths that keep critical project milestones on track and ensure treatments reach the patients who need them.

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited.

For more information visit: Piramal Pharma Solutions | LinkedIn| Facebook | X

About Piramal Pharma Limited

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.

For more information, visit: Piramal Pharma | LinkedIn

For Investor Queries:
Gagan Borana
Investor Relations & Enterprise Risk Management
gagan.borana@piramal.com

For Media Queries:
Madiha Vahid
Lead – Branding & Communications
madiha.vahid@piramal.com